Comparison of Bovine-Derived Hydroxyapatite and Autogenous Bone for Secondary Alveolar Bone Grafting in Patients With Alveolar Clefts

WOS: 000299214500016PubMed ID: 22182665Purpose: The aim of this retrospective study was to compare the long-term outcomes of secondary alveolar bone grafting (SABG) using bovine-derived hydroxyapatite versus autogenous bone. Patients and Methods: The subjects in this study were 23 patients with unilateral cleft lip and palate (13 male, 10 female) who underwent SABG from 2004 through 2009. The patients were recalled and examined to evaluate the success of the long-term outcomes of SABG. In group 1, there were 12 patients (7 male, 5 female) who underwent grafting with anterior iliac crest bone; in group 2, 11 patients (6 male, 5 female) underwent grafting with bovine-derived hydroxyapatite. Results: The mean ages at grafting were 13 +/- 3.76 years in group 1 and 10.82 +/- 2.6 years in group 2 (P = .134). The mean lengths of follow-up were 47.33 +/- 13.79 months in group 1 and 67.82 +/- 10.36 months in group 2 (P = .002). Pocket depth, periodontal index, and gingival index scores were similar and indicated acceptable periodontal status in the 2 groups. The results for patient satisfaction were not statistically different (P = .05). There was no statistically significant difference between the 2 groups when results of the Chelsea scale were analyzed (P = .05). The radiologic results showed an 83.4% success rate in group 1 and a 100% success rate in group 2 (P = .478). When the densitometric values for cleft sites were analyzed, the difference between the 2 groups was not statistically significant (P = .190). Conclusions: Bovine-derived hydroxyapatite is as successful as the iliac graft for the SABG procedure. (C) 2012 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 70: e95-e102, 201

Clinical and molecular evaluation of MEFV gene variants in the Turkish population: a study by the National Genetics Consortium

Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disorder with recurrent fever, abdominal pain, serositis, articular manifestations, erysipelas-like erythema, and renal complications as its main features. Caused by the mutations in the MEditerranean FeVer (MEFV) gene, it mainly affects people of Mediterranean descent with a higher incidence in the Turkish, Jewish, Arabic, and Armenian populations. As our understanding of FMF improves, it becomes clearer that we are facing with a more complex picture of FMF with respect to its pathogenesis, penetrance, variant type (gain-of-function vs. loss-of-function), and inheritance. In this study, MEFV gene analysis results and clinical findings of 27,504 patients from 35 universities and institutions in Turkey and Northern Cyprus are combined in an effort to provide a better insight into the genotype-phenotype correlation and how a specific variant contributes to certain clinical findings in FMF patients. Our results may help better understand this complex disease and how the genotype may sometimes contribute to phenotype. Unlike many studies in the literature, our study investigated a broader symptomatic spectrum and the relationship between the genotype and phenotype data. In this sense, we aimed to guide all clinicians and academicians who work in this field to better establish a comprehensive data set for the patients. One of the biggest messages of our study is that lack of uniformity in some clinical and demographic data of participants may become an obstacle in approaching FMF patients and understanding this complex disease